Target intelligence / Profile preview

Disintegrin and metalloproteinase with thrombospondin motifs 4 (for ADAMTS4) and Disintegrin and metalloproteinase with thrombospondin motifs 5 (for ADAMTS5) (ADAMTS4 and ADAMTS5)

Target
ADAMTS4 and ADAMTS5
Molecular classification
Enzyme (specifically metalloproteinase), Protease (matrix metalloproteinase family, metzincin superfamily)
01

Overview

ADAMTS4 and ADAMTS5 are secreted extracellular matrix metalloproteinases belonging to the ADAMTS family. Their primary function is to cleave large proteoglycans such as aggrecan, thereby driving cartilage matrix degradation, especially in osteoarthritis. Structurally, both proteins contain a signal peptide, pro-domain, catalytic metalloproteinase domain, disintegrin-like domain, and additional C-terminal ancillary domains including thrombospondin type 1 repeats, cysteine-rich domains, and spacer regions. They require activation via furin-mediated removal of the pro-domain and are strongly regulated by endogenous inhibitors, primarily TIMP-3. Their expression and activity are associated with cartilage erosion, cardiovascular disease, and other forms of tissue remodeling, making them critical therapeutic targets for musculoskeletal and cardiovascular disorders.

Other names
Aggrecanase-1Aggrecanase-2
02

Mechanism of action

Inhibition of catalytic metalloproteinase domain by specific inhibitors (e.g., batimastat, biphenyl compounds). Endogenous inhibition via TIMP-3 binding to the active site and ancillary domains.

03

Biological functions

Extracellular matrix degradationProteoglycan cleavage, especially aggrecan in cartilageTissue remodeling
04

Disease associations

Osteoarthritis (OA)Musculoskeletal degenerative diseases (e.g., lumbar disc degeneration, cartilage erosion)Cardiovascular disease (e.g., atherosclerosis, aortic aneurysm)Pathological tissue remodeling in various diseases
05

Safety considerations

Risk of impairing physiological ECM remodeling resulting in abnormal tissue structure or functionOff-target effects and lack of specificity in protease inhibition may affect other metalloproteinases
06

Interacting drugs

Batimastat (broad-spectrum metalloprotease inhibitor)

2 more in the full profile.

07

Biomarkers

Increased aggrecan fragments in cartilage are an indicator/severity marker for osteoarthritisReduced ADAMTS5 mRNA/protein in aortic tissue as marker for cardiovascular pathologies

Beyond the preview

Go deeper on Disintegrin and metalloproteinase with thrombospondin motifs 4 (for ADAMTS4) and Disintegrin and metalloproteinase with thrombospondin motifs 5 (for ADAMTS5) (ADAMTS4 and ADAMTS5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Disintegrin and metalloproteinase with thrombospondin motifs 4 (for ADAMTS4) and Disintegrin and metalloproteinase with thrombospondin motifs 5 (for ADAMTS5) (ADAMTS4 and ADAMTS5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call